business and electricity production business. Therefore, there was no similar type of business in the industry that can be used as a benchmark for comparison. Not include transaction related to the novation
16:26 น. 8 14.3% 14.8% 13.0% 3% 2.3% 1.9% 10.3% 9.6% 9.3% 11.6% 11.4% 11.5% 20.4% 21.0% 22.0% 41.1% 40.9% 42.3% Mar'18 Dec'17 Mar'17 Portion of Loans by Business Type Manufacturing and commercial
Table: Loans to Customers Classified by Type of Business (Unit: Million Baht) Loans to customers classified by type of business loans December December Variance 2018 2017 Amount (%YTD) Agricultural and
····················›››››››››››››››››--------::::::::::::::::::::::::::::::///////////////············››››››››››››››››››››› ····················›››››››››››››››››--------::::::::::::::::::::::::::::::///////////////············››››››››››››››››››››› ····················›››››››››››››››››--------::::::::::::::::::::::::::::::///////////////············››››››››››››››››››››› ····················›››››››››››››››››--------::::::::::::::::::::::::::::::///////////////············››››››››››››››››››››› ···...
quality of its insurance portfolio toward a loss ratio insurance type and also perform a serious cost control. And the Company is expected to turn profit in 2019. Please be informed accordingly. Sincerely
Company and its subsidiaries was THB 2,864.65 million which increased by THB 126.41 million or by 4.62% compared to 2018. The significant changes of each type of the revenues can be explained as follows: 1
www.interpharma.co.th Inter Pharma Co. Ltd. 140/9 ITF Tower, 9th Floor, Silom Road, Suriyawong, Bangrak, Bangkok 10500, Thailand. Tel. 02-634-0225 Fax 02-634-0135 www.interpharma.co.th Type of Revenue 2019 2018 Change MB
of each type of the revenue can be explained as follows: 1. REVENUE FROM SALES OF MANUFACTURING AND TRADING GOODS In 2019, the revenue of Company and its subsidiaries was THB 2,776.38 million, equaled
Baht 3,522 million. This transactions is regarded as Type 2 acquisition of assets according to the Notification of the Capital Market Supervisory Board No. Tor Jor 20/2551 Re: Rules on Entering into